TEAS Plus New Application

PTO- 1478

Approved for use through 10/31/2024. OMB 0651-0009

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.

---

PTO- 1478

Approved for use through 10/31/2024. OMB 0651-0009

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Trademark/Service Mark Application, Principal Register

TEAS Plus Application

Serial Number: 97627400

Filing Date: 10/11/2022

To the Commissioner for Trademarks:

MARK: GQ (Standard Characters, see mark)
The literal element of the mark consists of GQ. The mark consists of standard characters, without claim to any particular font style, size, or color.
The applicant, GeneQuine Biotherapeutics GmbH, a gesellschaft mit beschränkter haftung (gmbh) legally organized under the laws of Germany, having an address of
      Harburger Schlossstr. 6-12
      Hamburg 21079
      Germany
      XXXX

requests registration of the trademark/service mark identified above in the United States Patent and Trademark Office on the Principal Register established by the Act of July 5, 1946 (15 U.S.C. Section 1051 et seq.), as amended, for the following:

For specific filing basis information for each item, you must view the display within the Input Table.
International Class 001:  Biochemicals for in vitro and in vivo scientific use; Biological tissue cultures, other than for medical or veterinary purposes; Diagnostic preparations for scientific or research use; Diagnostic preparations, other than for medical or veterinary purposes

Priority based on foreign filing: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services and asserts a claim of priority based on European Union Trademark - EUTM application number 018733902, filed 07/15/2022.
INTENT TO PERFECT 44(d) : At this time, the applicant intends to rely on Section 44(e) as a basis for registration. If ultimately the applicant does not rely on Section 44(e) as a basis for registration, a valid claim of priority may be retained.


For specific filing basis information for each item, you must view the display within the Input Table.
International Class 005:  Vaccines; Analgesic preparations; Anti-arthritic compositions and preparations; Anti-cancer preparations; Anti-inflammatory preparations; Biological preparations for the treatment of cancer; Biological preparations for the treatment of musculoskeletal, genetic, metabolic, endocrine, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, nephrological, hematological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, infectious, dermatological, and immune system related diseases and disorders; Biological tissue cultures for medical purposes; Biological tissue cultures for veterinary purposes; Biological joint tissue (including bone, cartilage, synovium, tendon), skin tissue, liver or other patient or donor-derived tissue intended for subsequent implantation; Cells for medical or clinical use; Diagnostic agents, preparations and substances for medical purposes; Diagnostic preparations for medical or veterinary purposes; Drug testing kits comprised of medical diagnostic reagents and assays for testing body fluids; Gene therapy products, namely, genetically engineered tissues for transplant purposes; Human vaccine preparations; Medicaments for promoting recovery from tendon and muscle injuries and disorders and sports related injuries; Nucleic acid sequences and chemical reagents for medical and veterinary purposes; Pain relief medication; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations for the treatment and prevention of musculoskeletal, genetic, metabolic, endocrine, cardiovascular, cerebrovascular, cardiopulmonary, genitourinary, oncological, hepatological, nephrological, hematological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, infectious, dermatological, and immune system related diseases and disorders; Veterinary pharmaceutical preparations for the prevention of musculoskeletal, genetic, metabolic, endocrine, cardiovascular, pulmonary, genitourinary, oncological, hepatological, hematological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, infectious, dermatological, and immune system related diseases and disorders; Veterinary pharmaceutical preparations for the treatment of musculoskeletal, genetic, metabolic, endocrine, cardiovascular, pulmonary, genitourinary, oncological, hepatological, hematological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, infectious, dermatological, and immune system related diseases and disorders; Veterinary preparations, namely, pain relief medication; Veterinary vaccines

Priority based on foreign filing: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services and asserts a claim of priority based on European Union Trademark - EUTM application number 018733902, filed 07/15/2022.
INTENT TO PERFECT 44(d) : At this time, the applicant intends to rely on Section 44(e) as a basis for registration. If ultimately the applicant does not rely on Section 44(e) as a basis for registration, a valid claim of priority may be retained.


For specific filing basis information for each item, you must view the display within the Input Table.
International Class 040:  Biomanufacturing for others, namely, manufacturing of biologics, vaccines, non-viral or viral vectors, gene therapy products, cell therapy products using biological organisms in the manufacturing process; Custom manufacture of pharmaceuticals, biologics, vaccines, biotechnological products, non-viral or viral vectors, gene therapy products, cell therapy products by pharmaceutical compounders; Custom manufacture of pharmaceuticals, biologics, vaccines, biotechnological products, non-viral or viral vectors, gene therapy products, cell therapy products; Manufacturing process consulting; Manufacturing services for others in the field of pharmaceuticals, biologics, vaccines, non-viral or viral vectors, gene therapy products, cell therapy products; Technical support services, namely, providing technical advice related to the manufacture of biologics, gene therapy products, vaccines, non-viral or viral vectors

Priority based on foreign filing: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services and asserts a claim of priority based on European Union Trademark - EUTM application number 018733902, filed 07/15/2022.
INTENT TO PERFECT 44(d) : At this time, the applicant intends to rely on Section 44(e) as a basis for registration. If ultimately the applicant does not rely on Section 44(e) as a basis for registration, a valid claim of priority may be retained.


For specific filing basis information for each item, you must view the display within the Input Table.
International Class 042:  Consulting services in the field of pharmaceutical research and development; Providing reagent sample testing and diagnostic services for others for scientific research purposes; Research and development in the field of genetics, gene therapy, cell therapy, vaccines, biotechnological production, non-viral or viral vector production; drug development for prevention and treatment of musculoskeletal, genetic, ophthalmic, metabolic, endocrine, cardiovascular, cerebrovascular, cardiopulmonary, genitourinary, oncological, hepatological, nephrological, hematological, respiratory, neurological, gastrointestinal, hormonal, infectious, dermatological, and immune system related diseases and disorders; Research and development in the pharmaceutical and biotechnology fields; Research and development of vaccines and medicines; Scientific research and development; Scientific research consulting in the field of genetics, gene therapy, cell therapy, vaccines, biotechnological production, non-viral or viral vector production; Scientific research for medical purposes in the field of musculoskeletal, genetic, metabolic, endocrine, cardiovascular, cerebrovascular, cardiopulmonary, genitourinary, oncological, hepatological, nephrological, hematological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, infectious, dermatological, and immune system related diseases and disorders; Scientific research in the field of genetics and genetic engineering; Testing, inspection, research, or development of pharmaceutical preparations for gene therapy

Priority based on foreign filing: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services and asserts a claim of priority based on European Union Trademark - EUTM application number 018733902, filed 07/15/2022.
INTENT TO PERFECT 44(d) : At this time, the applicant intends to rely on Section 44(e) as a basis for registration. If ultimately the applicant does not rely on Section 44(e) as a basis for registration, a valid claim of priority may be retained.




The owner's/holder's proposed attorney information: Mark F. Warzecha. Other appointed attorneys are Mark R. Malek, Daniel C. Pierron, Kelly G. Swartz, and Jessica Honeycutt. Mark F. Warzecha of Widerman Malek, PL, is a member of the XX bar, admitted to the bar in XXXX, bar membership no. XXX, and the attorney(s) is located at
      1990 W. New Haven Ave., Ste 201
      Melbourne, Florida 32904
      United States
      321-255-2332(phone)
      321-255-2351(fax)
      MFW@USLegalTeam.com
The docket/reference number is 5091.00002.
Mark F. Warzecha submitted the following statement: The attorney of record is an active member in good standing of the bar of the highest court of a U.S. state, the District of Columbia, or any U.S. Commonwealth or territory.

The applicant hereby appoints Mark F. Warzecha of Widerman Malek, PL
      1990 W. New Haven Ave., Ste 201
      Melbourne Florida 32904
      United States
      321-255-2332(phone)
      321-255-2351(fax)
      MFW@USLegalTeam.com
as applicant's representative upon whom notice or process in the proceedings affecting the mark may be served.

The applicant's current Correspondence Information:

Mark F. Warzecha

PRIMARY EMAIL FOR CORRESPONDENCE: MFW@USLegalTeam.com        SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): kim@uslegalteam.com; jhoneycutt@uslegalteam.com Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the applicant owner/holder and the applicant owner's/holder's attorney, if appointed, and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).

A fee payment in the amount of $1000 has been submitted with the application, representing payment for 4 class(es).

Declaration

	Basis: If the applicant is filing the application based on use in commerce under 15 U.S.C. § 1051(a): The signatory believes that the applicant is the owner of the trademark/service mark sought to be registered; The mark is in use in commerce and was in use in commerce as of the filing date of the application on or in connection with the goods/services in the application; The specimen(s) shows the mark as used on or in connection with the goods/services in the application and was used on or in connection with the goods/services in the application as of the application filing date; and To the best of the signatory's knowledge and belief, the facts recited in the application are accurate. And/Or If the applicant is filing the application based on an intent to use the mark in commerce under 15 U.S.C. § 1051(b), § 1126(d), and/or § 1126(e): The signatory believes that the applicant is entitled to use the mark in commerce; The applicant has a bona fide intention to use the mark in commerce and had a bona fide intention to use the mark in commerce as of the application filing date on or in connection with the goods/services in the application; and To the best of the signatory's knowledge and belief, the facts recited in the application are accurate.
	To the best of the signatory's knowledge and belief, no other persons, except, if applicable, concurrent users, have the right to use the mark in commerce, either in the identical form or in such near resemblance as to be likely, when used on or in connection with the goods/services of such other persons, to cause confusion or mistake, or to deceive.
	To the best of the signatory's knowledge, information, and belief, formed after an inquiry reasonable under the circumstances, the allegations and other factual contentions made above have evidentiary support.
	The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. § 1001, and that such willful false statements and the like may jeopardize the validity of the application or submission or any registration resulting therefrom, declares that all statements made of his/her own knowledge are true and all statements made on information and belief are believed to be true.

Declaration Signature

Signature: /Mark F. Warzecha/   Date: 10/11/2022
Signatory's Name: Mark F. Warzecha
Signatory's Position: Attorney of Record, Florida Bar Member
Signatory's Phone Number: 321-255-2332
Signature method: Signed directly within the form
Payment Sale Number: 97627400
Payment Accounting Date: 10/11/2022

Serial Number: 97627400
Internet Transmission Date: Tue Oct 11 14:41:55 ET 2022
TEAS Stamp: USPTO/FTK-XX.XXX.XX.XX-20221011144157025
744-97627400-8201eda307b8b68a4afba795768
227f4c20598455ee6d6af2a9d1ce6658ce5d1d6c
-CC-41550962-20221011143905412366